NBDF/LinkedIn
Sep 10, 2025, 20:45
FDA Approves VONVENDI for Adults With All Types of von Willebrand Disease
National Bleeding Disorders Foundation (NBDF) shared on LinkedIn:
”Big news for the bleeding disorders community:
The FDA has expanded approval of VONVENDI® to include prophylactic use for adults with all types of von Willebrand disease (VWD).
This marks an important step forward in reducing bleeding episodes and improving quality of life.”
Read more here.
Stay updated on the emerging in the field of bleeding disorders with Hemostasis Today.
-
Oct 10, 2026, 10:55Tzu-Fei Wang: How Should We Approach Anticoagulation in Patients with Cancer-Associated Gonadal and Renal Vein Thrombosis?
-
Oct 10, 2026, 10:50Robert Sidonio Joins ATHN Advanced Clinical Research Fellowship Program
-
Oct 10, 2026, 10:45Federica Fogacci: Co-Moderating at CA Meet 2026 in Padua – Elevating Lifestyle Interventions in Cardiology
-
Oct 10, 2026, 10:40Juan Cristóbal Morales Muñoz: Pharmacokinetic Profiling of Factor VIII Concentrates in Chilean Patients
-
Oct 10, 2026, 10:32Randall Schaefer: When Your Prehospital Agency Reports Blood Product Wastage Rates, What is it Really Reporting?
-
Oct 10, 2026, 10:26Simone Strasser: ROTEM-Guided Transfusion Cuts Blood Product Use in Patients with Cirrhosis
-
Oct 10, 2026, 10:18Jérôme S.: WHO Launches Global Roadmap to Combat Hypertensive Disorders of Pregnancy
-
Oct 10, 2026, 10:07Maha Othman: Look Forward to an Amazing ISTH 2027 in Vancouver!
-
Oct 10, 2026, 10:02Rucha Patil: National Convening Highlights Opportunities for Equitable Hemophilia Care Across India